Impax Laboratories Company Profile (NASDAQ:IPXL)

Analyst Ratings

Consensus Ratings for Impax Laboratories (NASDAQ:IPXL) (?)
Ratings Breakdown: 1 Sell Rating(s), 9 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Hold (Score: 2.21)
Consensus Price Target: $40.45 (28.75% upside)

Analysts' Ratings History for Impax Laboratories (NASDAQ:IPXL)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016Leerink SwannReiterated RatingMarket Perform$31.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016BMO Capital MarketsInitiated CoverageMarket Perform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Piper Jaffray Cos.Reiterated RatingOverweight$41.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/22/2016Deutsche Bank AGLower Price TargetHold$42.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Bank of America Corp.UpgradeUnderperform -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Goldman Sachs Group Inc.Initiated CoverageSell$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016JPMorgan Chase & Co.Initiated CoverageNeutral$47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016Northland SecuritiesInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/15/2016BTIG ResearchReiterated RatingBuy$48.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016NomuraReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016SusquehannaLower Price TargetPositive$55.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016Royal Bank Of CanadaLower Price TargetSector Perform$48.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/17/2016Raymond James Financial Inc.UpgradeUnderperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2015GuggenheimReiterated RatingBuy$53.50 -> $60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/6/2015JMP SecuritiesBoost Price TargetMarket Outperform$48.00 -> $56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2015Needham & Company LLCBoost Price TargetBuy$37.00 -> $46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/9/2015WallachBeth CapitalBoost Price TargetBuy$35.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/30/2014WunderlichDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Impax Laboratories (NASDAQ:IPXL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116$0.39$0.43$241.84 million$226.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2016Q415$0.44$0.62$223.23 million$282.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315$0.39$0.40$214.69 million$221.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215$0.35$0.34$200.68 million$214.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115$0.18$0.09$146.00 million$143.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q414$0.12$0.16$125.50 million$131.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314$0.31$0.33$148.36 million$145.63 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214$0.36$0.60$155.97 million$188.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114$0.05$0.24$97.80 million$118.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2014Q413$0.03($0.14)$119.01 million$100.74 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2013Q313($0.08)$0.25$111.83 million$115.75 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013$0.04$0.08$120.75 million$129.63 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2013Q1 2013$0.21$0.37$129.12 million$148.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2013Q4 2012$0.19$0.30$127.03 million$141.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2012Q312$0.49$0.48$160.76 million$145.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2012$0.44$0.60ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2012$0.45$0.52ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2012$0.19$0.33ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011$0.20$0.30ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2011$0.18$0.19ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011$0.15$0.21ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2011$0.22$0.23ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Impax Laboratories (NASDAQ:IPXL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.39$0.51$0.45
Q2 20161$0.33$0.33$0.33
Q3 20161$0.47$0.47$0.47
Q4 20161$0.49$0.49$0.49
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Impax Laboratories (NASDAQ:IPXL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Impax Laboratories (NASDAQ:IPXL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/11/2015Mark A SchlossbergSVPSell7,457$43.30$322,888.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Michael NestorInsiderSell5,000$43.56$217,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Michael MarkbreiterDirectorSell28,000$41.70$1,167,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2015Mark A SchlossbergSVPSell4,649$43.41$201,813.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2015Peter R TerreriDirectorSell4,833$43.93$212,313.69View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2015Michael MarkbreiterDirectorSell19,399$42.24$819,413.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014Larry HsuDirectorSell100,000$28.38$2,838,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Peter R TerreriDirectorSell3,000$28.00$84,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Larry HsuDirectorSell50,000$27.22$1,361,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Larry HsuDirectorSell3,800$26.53$100,814.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2014Nigel FlemingDirectorSell1,900$25.72$48,868.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Nigel FlemingDirectorSell1,333$26.58$35,431.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2014Michael MarkbreiterDirectorSell12,500$26.44$330,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014Larry HsuDirectorSell219,386$26.28$5,765,464.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2014Michael MarkbreiterDirectorSell4,000$27.54$110,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2014Robert BurrDirectorSell1,500$24.31$36,465.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2013Robert BurrDirectorSell1,500$22.98$34,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2013Robert BurrDirectorSell1,500$20.10$30,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2013Robert BurrDirectorSell1,500$20.87$31,305.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Robert BurrDirectorSell1,500$21.15$31,725.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2013Robert L BurrDirectorSell1,500$20.26$30,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Robert L BurrDirectorSell1,500$18.80$28,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2013Robert L BurrDirectorSell1,500$16.35$24,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2013Peter R TerreriDirectorSell3,450$17.39$59,995.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2013Larry HsuCEOBuy7,000$16.88$118,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2013Mark A SchlossbergSVPBuy1,000$16.73$16,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2013Robert L BurrDirectorSell1,500$19.82$29,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2012Robert L BurrDirectorSell1,500$19.86$29,790.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2012Nigel FlemingDirectorSell6,000$23.99$143,940.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Impax Laboratories (NASDAQ:IPXL)
DateHeadline
07/27/16 04:57 PMShort Interest Expands By 12.8% For IPXL
07/22/16 06:43 AM4 Low P/CF Stocks to Improve Your Value Investing -
07/21/16 03:43 PMIMPAX LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers -
07/21/16 03:02 PMImpax Names Douglas S. Boothe President of Generics Division - [PR Newswire] - HAYWARD, Calif., July 21, 2016 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today announced that it has filled a key executive leadership role, appointing ...
07/19/16 01:40 PMImpax Laboratories, Inc. – Value Analysis (NASDAQ:IPXL) : July 19, 2016 -
07/13/16 06:47 AMTeva Raises Q2 Guidance; to Unveil 2016-2019 View -
07/07/16 07:31 AMImpax to Report Second Quarter 2016 Results on August 9, 2016 - [at noodls] - HAYWARD, Calif., July 7, 2016 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its second quarter 2016 financial results on Tuesday, August 9, 2016, ...
06/28/16 10:27 AM[$$] Teva and Allergan Sell Generic Drugs to Impax In Latest Divestiture -
06/23/16 07:36 AMLeerink Affirms Impax Labs (IPXL) at 'Market Perform'; Teva Deal Positive, But Base Outlook Isn't
06/23/16 07:36 AMImpax Laboratories Inc. (IPXL) Is Losing Ground After Acquisition
06/23/16 07:36 AMImpax Posting Steep Loss On Acquisition Of Generic Products
06/23/16 07:36 AMBank of America (Merrill Lynch) announced (NASDAQ:IPXL) Impax Laboratories Inc., sustaining its target price to $0 today
06/21/16 05:01 PMEast Bay drug maker grabs $586M deal, clearing path for bigger generics pact - Impax Laboratories Inc. reached a deal Tuesday with Teva Pharmaceutical Industries and affiliates of Allergan to buy a broad portfolio of generic products for a total price of $586 million. The sale, covering products from Teva and Allerga, was required by the Federal Trade Commission as a condition to the agency approving Teva’s proposed $40.5 billion acquisition of Allergan’s worldwide generics business. The portfolio of products that Hayward-based Impax (NASDAQ: IPXL) is buying includes…
06/21/16 04:24 PMWhy Is Impax Labs Tumbling 11.7% Today
06/21/16 04:24 PMImpax Labs To Acquire Generic Products; Lifts FY Adj. EPS Growth View
06/21/16 04:24 PMImpax splashes out $586mln on Allergan and Teva's generics cast-offs
06/21/16 04:24 PMOversold Conditions For Impax Laboratories (IPXL)
06/21/16 04:17 PMWhy Impax Laboratories, Werner Enterprises, and Planet Fitness Slumped Today -
06/13/16 07:44 AMImpax Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IPXL-US : June 13, 2016 -
06/06/16 04:37 PMGoldman Initiates Impax Labs With Sell Rating, $33 Target
06/06/16 09:14 AMSpecialty Pharma: After the M&A Fueled Super Cycle -
06/06/16 06:23 AMCoverage initiated on Impax Labs by Goldman -
06/04/16 04:40 PMCommit To Buy Impax Laboratories At $30, Earn 12% Annualized Using Options
06/02/16 03:25 PMImpax to Present at the Goldman Sachs 37th Annual Global Healthcare Conference - [at noodls] - HAYWARD, Calif., June 2, 2016 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Goldman Sachs 37 Annual Global Healthcare Conference on Wednesday, ...
06/02/16 03:17 PMIMPAX LABORATORIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement -
05/28/16 12:30 PMImpax Laboratories, Inc. (NASDAQ:IPXL) One-Year Price Target At $39.31 - Investor Newswire - Impax Laboratories, Inc. (NASDAQ:IPXL) One-Year Price Target At $39.31Investor NewswireFirst Call has set a 52-week price target of $39.31 on Impax Laboratories, Inc. (NASDAQ:IPXL) stock after completion of its survey. For the approaching quarter, EPS estimate is set at $0.43 and for underway fiscal at $1.75. This estimate for next year ...and more »
05/27/16 01:31 PMEarnings Review and Stock Rundown for Impax Laboratories, Inc. (NASDAQ:IPXL) - Wall Street Hints and News - Earnings Review and Stock Rundown for Impax Laboratories, Inc. (NASDAQ:IPXL)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Impax Laboratories, Inc. (NASDAQ:IPXL) to ...and more »
05/26/16 07:21 AMImpax Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IPXL-US : May 26, 2016 -
05/25/16 12:22 PMImpax Laboratories, Inc. (NASDAQ:IPXL) Closes At $32.12 - Investor Newswire - Impax Laboratories, Inc. (NASDAQ:IPXL) Closes At $32.12Investor NewswireYesterday, the stock of Impax Laboratories, Inc. (NASDAQ:IPXL) closed at $32.12 after opening at $32.19 and registering high of $32.67 and low of $32.08. The last price is $-18.95 off 1-year high of $51.42 and $4.85 away from low of $27.62 during same ...Impax Laboratories, Inc. (NASDAQ:IPXL) Latest Broker CoverageRisers & FallersImpax Laboratories Incorporated (NASDAQ:IPXL) Shorted Shares Decreased By 9.64%The PostImpax Laboratories, Inc. (NASDAQ:IPXL) Quarterly EPS From Continuing Operations Stands At $-0.1473Equities Focusall 10 news articles »
05/21/16 12:11 PMRevenue Update on Impax Laboratories Inc(NASDAQ:IPXL) - Trade Calls - Revenue Update on Impax Laboratories Inc(NASDAQ:IPXL)Trade CallsImpax Laboratories Inc(NASDAQ:IPXL) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 10, 2016. Company reported revenue of $225.51M. Analysts estimated a revenue of $247.20M. Earnings per ...Are Analysts Bearish Impax Laboratories Inc (NASDAQ:IPXL) After Last Week?Franklin IndependentImpax Laboratories, Inc. (NASDAQ:IPXL) Hovering Around $30.89Markets DailyValuable Price Trends to Observe: Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) , Impax Laboratories, Inc. (NASDAQ ...Street Updatesall 4 news articles »
05/18/16 05:27 PMShkreli's former company beats Impax demand to block drug sales - [Reuters] - Turing Pharmaceuticals does not have to recall thousands of bottles of a life-saving medicine that became the flashpoint of a pricing controversy after former Chief Executive Martin Shkreli raised its price by over 5,000 percent, a U.S. judge ruled on Wednesday. U.S. District Judge Edgardo Ramos in Manhattan denied a request by Impax Laboratories Inc to enjoin Turing from selling over 3,500 Daraprim bottles and recall potentially thousands more that carried the label of one of Impax's units. Impax, which sued Turing earlier this month, argued an injunction was necessary to protect it from significant regulatory liability linked to Turing's decision to raise the price of Daraprim.
05/18/16 12:55 PMPrice Review of Stocks: Impax Laboratories, Inc. (NASDAQ:IPXL) , Intersect ENT, Inc. (NASDAQ:XENT) - Street Updates - Price Review of Stocks: Impax Laboratories, Inc. (NASDAQ:IPXL) , Intersect ENT, Inc. (NASDAQ:XENT)Street UpdatesOn 5/13/2016, shares of Impax Laboratories, Inc. (NASDAQ:IPXL) rose +2.10% in trading session and finally closed at $29.18. The company most recent volume stood at 741.94 thousand shares as compared to its average volume of 781.08 thousand shares.Stock on Downward Trajectory: Impax Laboratories Inc. (NASDAQ:IPXL)Franklin IndependentImpax Laboratories Incorporated (NASDAQ:IPXL) Short Interest Decreased By 9.64%The Postall 4 news articles »
05/18/16 12:04 PMIMPAX LABORATORIES INC Financials -
05/18/16 06:49 AMIMPAX LABORATORIES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submissio -
05/17/16 02:04 PMImpax Laboratories, Inc. :IPXL-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/12/16 06:55 AMEarnings Expectation Watch List: Impax Laboratories Inc (NASDAQ:IPXL) - News Oracle - News OracleEarnings Expectation Watch List: Impax Laboratories Inc (NASDAQ:IPXL)News OracleLast Trade: The Company fell -2.96% and finished at $29.49. The daily volume was measured at 1.91 million shares. The 52-week high of the share price is $51.42 and the 52-week low is $28.92. The company has a market cap of $2.36 billion. Its latest ...and more »
05/12/16 06:55 AMImpax Laboratories Inc. (IPXL) is Trading Lower on Unusual Volume for May 10 - Equities.com - Impax Laboratories Inc. (IPXL) is Trading Lower on Unusual Volume for May 10Equities.comImpax Laboratories Inc. (IPXL) experienced unusually high volume on May. 10, as the stock lost 2.96% to a closing price of $29.49. The stock saw 1.92 million shares trade hands over the course of the day on 13,440 trades. Given that the stock's average ...
05/11/16 06:11 AMBest stocks to view: Abbott Laboratories (NYSE:ABT) , Impax Laboratories, Inc. (NASDAQ:IPXL) - Is stories - Is storiesBest stocks to view: Abbott Laboratories (NYSE:ABT) , Impax Laboratories, Inc. (NASDAQ:IPXL)Is storiesAbbott Laboratories (NYSE:ABT) increased +0.32% to $38.10 while traded 11.23 million shares on 5/10/2016. The stock price negotiated for value between $37.78 to $38.30 in recent trading session. During the past 52 weeks, the stock's price witnessed a ...and more »
05/11/16 06:11 AMImpax Laboratories, Inc. (NASDAQ:IPXL) Latest Impact Score At 90 - RealistInvestor.com - Impax Laboratories, Inc. (NASDAQ:IPXL) Latest Impact Score At 90RealistInvestor.comImpax Laboratories, Inc. (NASDAQ:IPXL) has a 0 daily sentiment score given by Alpha One after scanning articles on various online news platform. Alpha One performs algorithm based analysis to reach stock sentiment based on content published on ...and more »
05/11/16 06:11 AMImpax Laboratories Inc. (IPXL) is Trading Higher on Unusual Volume for May 09 - Equities.com - NewsWay 21Impax Laboratories Inc. (IPXL) is Trading Higher on Unusual Volume for May 09Equities.comImpax Laboratories Inc. (IPXL) experienced unusually high volume on May. 09, as the stock gained 1.98% to a closing price of $30.39. The stock saw 973,804 shares trade hands over the course of the day on 9,488 trades. Given that the stock's average ...Impax Laboratories Inc (IPXL) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPSNewsWay 21Upgrades And Downgrades For Impax Laboratories, Inc. (NASDAQ:IPXL)Risers & FallersImpax Laboratories Incorporated (NASDAQ:IPXL) Shorted Shares Increased By 1.28%B.O.D.Y ConfidentialMarket Digest -Web Breaking News -Sonoran Weekly Reviewall 13 news articles »
05/10/16 03:32 PMEdited Transcript of IPXL earnings conference call or presentation 10-May-16 12:30pm GMT -
05/10/16 07:09 AMIMPAX LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, F -
05/10/16 06:07 AMQ1 2016 Impax Laboratories Inc Earnings Release - Before Market Open -
05/10/16 05:48 AMImpax Labs reports 1Q loss -
05/10/16 05:48 AMImpax Reports First Quarter 2016 Financial Results - [at noodls] - HAYWARD, Calif., May 10, 2016 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported first quarter 2016 financial results for the quarter ended March ...
05/10/16 05:45 AM6:45 am Impax Labs beats by $0.03, misses on revs -
05/09/16 08:03 AMSpecialty Pharma Stocks to Report Q1 on May 10: AGN, IPXL -
05/09/16 07:48 AMIs a Surprise Coming for Impax Laboratories (IPXL) This Earnings Season? -
05/09/16 06:31 AMAfter Last Week What Do Analysts Think Of Impax Laboratories, Inc. (NASDAQ:IPXL) - Share Trading News - After Last Week What Do Analysts Think Of Impax Laboratories, Inc. (NASDAQ:IPXL)Share Trading News02/11/2015 – Impax Laboratories, Inc. was downgraded to “neutral” by analysts at Goldman Sachs. They now have a USD 41 price target on the stock. The share price of Impax Laboratories, Inc. (NASDAQ:IPXL) was down -7.65% during the last trading ...and more »
05/07/16 06:18 AMEarnings Outlook on Impax Laboratories, Inc. (NASDAQ:IPXL) - B.O.D.Y Confidential - Earnings Outlook on Impax Laboratories, Inc. (NASDAQ:IPXL)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Impax Laboratories, Inc. (NASDAQ:IPXL)'s next earnings release which is expected to be posted on or around 2016-05-10. Sell-side research firms on Wall Street are expecting that the company will post EPS of ...and more »

Social

About Impax Laboratories

Impax Laboratories logoImpax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: IPXL
  • CUSIP: 45256B10
Key Metrics:
  • Previous Close: $31.42
  • 50 Day Moving Average: $30.54
  • 200 Day Moving Average: $33.11
  • P/E Ratio: 66.01
  • P/E Growth: 0.74
  • Market Cap: $2.23B
  • Beta: 1.16
  • Current Year EPS Consensus Estimate: $1.77 EPS
  • Next Year EPS Consensus Estimate: $2.55 EPS
Additional Links:
Impax Laboratories (NASDAQ:IPXL) Chart for Saturday, July, 30, 2016